Please assess the completion status of the following clinical trial:

Trial Title: PET/MR for Rectal Cancer Treatment Monitoring and Surveillance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Biopsy-proven rectal adenocarcinoma of the rectum with clinically suspected or previously known stage I-IIIB (cT1-4, N0-2, M0) disease~* Anticipated or prior chemoradiation as part of an NOM treatment strategy~* Ability to understand and willingness to sign an IRB-approved written informed consent document~Exclusion Criteria:~* Prior surgical resection of rectal cancer (endoscopic or TME)~* Contraindication to MRI~* Comorbidities that would limit patient's ability to cooperate with a PET/MRI examination (e.g. dementia, inability to follow commands, claustrophobia, tremors, requirement for oxygen by nasal cannula, etc...).~* Implanted devices or materials that may interfere with MRI imaging or create significant artifact~* Pregnancy~* Contraindication to gadolinium contrast or FDG~* End-stage renal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FDG PET/MRI (Type: EXPERIMENTAL): -Patients will undergo FDG-PET/MRI in lieu of the standard pelvic MRI at up to 6 time-points at which it would normally be performed in their care for the period of time extending 30-36 months from the time of enrollment (depending on enrollment point). In the surveillance period, when patients typically undergo pelvic MRI every 3 months, the FDG-PET/MRI will be done in lieu of the standard pelvic MRI on an approximately every-other-scan basis. In other words, the FDG-PET/MRI will occur roughly once every 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).